We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+27.07%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$39.1B
AUM Growth
+$5.57B
(+17%)
Cap. Flow
-$1.33B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
25.2%
Holding
834
New
111
Increased
262
Reduced
309
Closed
110
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$2.28B |
| 2 |
Otis Worldwide
OTIS
|
+$193M |
| 3 |
Burlington
BURL
|
+$191M |
| 4 |
AbbVie
ABBV
|
+$178M |
| 5 |
Wayfair
W
|
+$144M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.66B |
| 2 |
Lockheed Martin
LMT
|
+$339M |
| 3 |
Johnson & Johnson
JNJ
|
+$262M |
| 4 |
Pfizer
PFE
|
+$167M |
| 5 |
Target
TGT
|
+$141M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.52% |
| 2 | Healthcare | 19.78% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Financials | 11.33% |
| 5 | Industrials | 8.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Zimmer Biomet
ZBH
$19.1B
| $28.6M | 0.07% |
246,831
+5,287
| +2% | +$609K |
|
|
SCHW
302
Charles Schwab
SCHW
$187B
| $28.6M | 0.07% |
+846,625
| New | +$30.3M |
|
303
Gates Industrial Corporation Ltd.
GTES
$7.47B
| $28.4M | 0.07% |
2,759,597
+38,066
| +1% | +$345K |
|
304
nVent Electric
NVT
$26.6B
| $28.3M | 0.07% |
1,508,513
-910,026
| -38% | -$16.6M |
|
305
ProQR Therapeutics
PRQR
$270M
| $27.7M | 0.07% |
4,550,062
| – | – |
|
306
Vertiv
VRT
$107B
| $27.1M | 0.07% |
1,999,623
+1,514,623
| +312% | +$17.6M |
|
307
HP
HPQ
$26B
| $27M | 0.07% |
1,551,836
-160,100
| -9% | -$2.54M |
|
308
F5
FFIV
$23.4B
| $27M | 0.07% |
193,400
+122,400
| +172% | +$16.5M |
|
309
State Street
STT
$51.6B
| $27M | 0.07% |
424,400
+9,000
| +2% | +$543K |
|
310
Emerson Electric
EMR
$91.3B
| $26.9M | 0.07% |
433,340
-934,642
| -68% | -$53.1M |
|
311
Halozyme
HALO
$9.96B
| $26.8M | 0.07% |
1,000,000
+300,000
| +43% | +$6.77M |
|
312
Spyre Therapeutics
SYRE
$8.87B
| $26.8M | 0.07% |
115,680
+56,936
| +97% | +$10.8M |
|
313
American Water Works
AWK
$26.3B
| $26.6M | 0.07% |
+206,499
| New | +$25.7M |
|
314
Cadence Design Systems
CDNS
$93B
| $26.5M | 0.07% |
276,300
-44,400
| -14% | -$3.72M |
|
315
PPG Industries
PPG
$26.5B
| $26.5M | 0.07% |
249,628
-18,170
| -7% | -$1.75M |
|
316
Marriott International
MAR
$93.8B
| $26.4M | 0.07% |
308,125
+900
| +0.3% | +$78.2K |
|
|
ICPT
317
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $26.4M | 0.07% |
+550,000
| New | +$42.5M |
|
318
First Horizon
FHN
$12.5B
| $26.3M | 0.07% |
+2,641,869
| New | +$24M |
|
319
T. Rowe Price
TROW
$24.7B
| $26.3M | 0.07% |
212,930
-5,100
| -2% | -$582K |
|
320
Southwest Airlines
LUV
$24.2B
| $26.3M | 0.07% |
768,677
+228,600
| +42% | +$7.26M |
|
321
Cintas
CTAS
$80.7B
| $26.1M | 0.07% |
391,200
+13,600
| +4% | +$786K |
|
|
AMK
322
DELISTED
AssetMark Financial Holdings, Inc.
AMK
| $25.9M | 0.07% |
948,523
-179,010
| -16% | -$4.38M |
|
323
Labcorp
LH
$25.4B
| $25.7M | 0.07% |
180,304
+54,708
| +44% | +$7.57M |
|
324
McCormick & Company Non-Voting
MKC
$14.1B
| $25.7M | 0.07% |
286,830
+9,600
| +3% | +$791K |
|
325
CarMax
KMX
$8.09B
| $25.5M | 0.07% |
284,400
+197,000
| +225% | +$15.4M |
|
Similar funds
Adage Capital Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Adage Capital Partners held 834 positions worth $39.1B, up 17% from $33.5B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Adage Capital Partners withdrew a net $1.33B in Q2 2020, closing 110 positions and reducing 309 holdings. Its most notable exit was Allergan plc, an estimated $1.66B position sold in full.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Adage Capital Partners opened a new position in Royalty Pharma worth $2.23B.
- Adage Capital Partners's largest Q2 2020 buy was Royalty Pharma: 46,015,330 shares worth $2.23B.
- Adage Capital Partners added most to Burlington in Q2 2020, an estimated $191M increase.
- Adage Capital Partners's biggest Q2 2020 reduction was Lockheed Martin, cutting an estimated $339M.
- Adage Capital Partners fully exited Allergan plc in Q2 2020, selling an estimated $1.66B.
- Adage Capital Partners's ten largest holdings make up 25% of its $39.1B portfolio in Q2 2020.
- Adage Capital Partners opened 111 new positions and closed 110 in Q2 2020.
- Adage Capital Partners's portfolio value rose 17% quarter-over-quarter to $39.1B.
Based on Adage Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.